返回 Agenda
Session 2: Quality Considerations - Part One
Session Chair(s)
Sundar Ramanan, PhD
Director, Global Biosimilars R&D Policy
Amgen Inc., United States
Speaker(s)
FDA Address
Steven Kozlowski, MD
FDA, United States
Director, Office of Biotechnology Products, OPQ, CDER
Challenges and Approaches in Demonstrating Biosimilarity and How to Move Toward Fingerprint-Like Equivalence
Joseph L Glajch
Momenta Pharmaceuticals, United States
Director, Analytical Development
Defining the Requisite Components of Interchangeability
Paul Tebbey, PhD, MBA
AbbVie, Inc., United States
Therapeutic Area Lead, Biotherapeutics Global Medical Affairs
PROFILE-NMR: Assessing Higher Order Structure of Formulated Protein Therapeutics
Brad Jordan, PhD
Eli Lilly and Company, United States
Associate Vice President, Regulatory Policy and Strategy